Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

In cancer drug resistance, germline matters too.

Cheng EH, Sawyers CL.

Nat Med. 2012 Apr 5;18(4):494-6. doi: 10.1038/nm.2725. No abstract available.

PMID:
22481406
2.

The BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia.

Chen X, Liu H, Xing H, Sun H, Zhu P.

Nat Med. 2014 Oct;20(10):1090. doi: 10.1038/nm.3638. No abstract available.

PMID:
25295932
3.

Reply: the BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia.

Ong ST, Chuah CT, Ko TK, Hillmer AM, Lim WT.

Nat Med. 2014 Oct;20(10):1090-1. doi: 10.1038/nm.3652. No abstract available.

PMID:
25295933
4.

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, Ariyaratne PN, Takahashi N, Sawada K, Fei Y, Soh S, Lee WH, Huang JW, Allen JC Jr, Woo XY, Nagarajan N, Kumar V, Thalamuthu A, Poh WT, Ang AL, Mya HT, How GF, Yang LY, Koh LP, Chowbay B, Chang CT, Nadarajan VS, Chng WJ, Than H, Lim LC, Goh YT, Zhang S, Poh D, Tan P, Seet JE, Ang MK, Chau NM, Ng QS, Tan DS, Soda M, Isobe K, Nöthen MM, Wong TY, Shahab A, Ruan X, Cacheux-Rataboul V, Sung WK, Tan EH, Yatabe Y, Mano H, Soo RA, Chin TM, Lim WT, Ruan Y, Ong ST.

Nat Med. 2012 Mar 18;18(4):521-8. doi: 10.1038/nm.2713.

PMID:
22426421
5.

The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy.

Ying HQ, Chen J, He BS, Pan YQ, Wang F, Deng QW, Sun HL, Liu X, Wang SK.

Sci Rep. 2015 Jun 15;5:11348. doi: 10.1038/srep11348.

6.

The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia.

Ko TK, Chin HS, Chuah CT, Huang JW, Ng KP, Khaw SL, Huang DC, Ong ST.

Oncotarget. 2016 Jan 19;7(3):2721-33. doi: 10.18632/oncotarget.5436.

7.

The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.

Zhao M, Zhang Y, Cai W, Li J, Zhou F, Cheng N, Ren R, Zhao C, Li X, Ren S, Zhou C, Hirsch FR.

Cancer. 2014 Aug 1;120(15):2299-307. doi: 10.1002/cncr.28725. Epub 2014 Apr 15.

8.

FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.

Kiyota M, Kuroda J, Yamamoto-Sugitani M, Shimura Y, Nakayama R, Nagoshi H, Mizutani S, Chinen Y, Sasaki N, Sakamoto N, Kobayashi T, Matsumoto Y, Horiike S, Taniwaki M.

Apoptosis. 2013 Nov;18(11):1437-46. doi: 10.1007/s10495-013-0882-y.

PMID:
23851982
9.

The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients.

Katagiri S, Umezu T, Ohyashiki JH, Ohyashiki K.

Br J Haematol. 2013 Jan;160(2):269-71. doi: 10.1111/bjh.12111. Epub 2012 Nov 1. No abstract available.

PMID:
23116058
10.

A novel BIM deletion polymorphism: implications and lessons for cancer targeted therapies.

Soh S, Ong ST.

Rinsho Ketsueki. 2013 Oct;54(10):1714-9. Review. No abstract available.

PMID:
24064821
11.

EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.

Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S, Ishikawa D, Sato M, Hasegawa Y, Sekido Y, Yano S.

Cancer Res. 2013 Apr 15;73(8):2428-34. doi: 10.1158/0008-5472.CAN-12-3479. Epub 2013 Feb 4.

12.

DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia.

Leo E, Mancini M, Aluigi M, Castagnetti F, Martinelli G, Barbieri E, Santucci MA.

Br J Haematol. 2012 Nov;159(3):373-6. doi: 10.1111/bjh.12023. Epub 2012 Aug 25. No abstract available.

PMID:
22924699
13.

Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.

Lee JK, Shin JY, Kim S, Lee S, Park C, Kim JY, Koh Y, Keam B, Min HS, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS, Lee SH, Kim JI.

Ann Oncol. 2013 Aug;24(8):2080-7. doi: 10.1093/annonc/mdt127. Epub 2013 Apr 4.

PMID:
23559152
14.

Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer.

Lee JH, Lin YL, Hsu WH, Chen HY, Chang YC, Yu CJ, Shih JY, Lin CC, Chen KY, Ho CC, Laio WY, Yang PC, Yang JC.

J Thorac Oncol. 2014 Sep;9(9):1385-92. doi: 10.1097/JTO.0000000000000238.

15.

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.

Lee JY, Ku BM, Lim SH, Lee MY, Kim H, Kim M, Kim S, Jung HA, Sun JM, Ahn JS, Park K, Ahn MJ.

J Thorac Oncol. 2015 Jun;10(6):903-9. doi: 10.1097/JTO.0000000000000535.

16.

Clinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation.

Isobe K, Hata Y, Tochigi N, Kaburaki K, Kobayashi H, Makino T, Otsuka H, Sato F, Ishida F, Kikuchi N, Hirota N, Sato K, Sano G, Sugino K, Sakamoto S, Takai Y, Shibuya K, Iyoda A, Homma S.

J Thorac Oncol. 2014 Apr;9(4):483-7. doi: 10.1097/JTO.0000000000000125.

17.

BCL2-like 11 intron 2 deletion polymorphism is not associated with non-small cell lung cancer risk and prognosis.

Cho EN, Kim EY, Jung JY, Kim A, Oh IJ, Kim YC, Chang YS.

Lung Cancer. 2015 Oct;90(1):106-10. doi: 10.1016/j.lungcan.2015.07.017. Epub 2015 Aug 1.

PMID:
26271547
18.

DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia.

Leo E, Mancini M, Castagnetti F, Gugliotta G, Santucci MA, Martinelli G.

J Cell Biochem. 2015 Apr;116(4):589-97. doi: 10.1002/jcb.25010.

PMID:
25389112
19.

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.

Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S.

PLoS Med. 2007 Oct;4(10):1669-79; discussion 1680.

20.

BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer.

Li Z, Zhou S, Zhang L, Su C, Hang J, Zhao Y, Su B, Zhou C.

Med Oncol. 2011 Jun;28(2):572-7. doi: 10.1007/s12032-010-9470-y. Epub 2010 Mar 17.

PMID:
20237869

Supplemental Content

Support Center